IOVANCE BIOTHERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Payments to Acquire Debt Securities, Available-for-sale of $185.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $129.61M, a 88.67% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $56.00M, a 42.81% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $59.91M, a 32.05% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $92.14M, a 41.13% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $318.67M, a 30.84% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $460.77M, a 123.78% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $205.90M, a 16.24% decline from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $245.82M, a 66.10% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $129.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $185.61M 10-Q · filed 2026-08-06 | $245.51M derived: sum of 3 quarters · filed 2026-08-06 | $337.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $56.00M 10-Q · filed 2026-05-07 | $115.90M derived: sum of 2 quarters · filed 2026-05-07 | $208.05M derived: sum of 3 quarters · filed 2026-05-07 | $276.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $59.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $152.05M derived: sum of 2 quarters · filed 2026-02-24 | $220.75M derived: sum of 3 quarters · filed 2026-08-06 | $318.67M 10-K · filed 2026-02-24 |
| 2025-09-30 | $92.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $160.84M derived: sum of 2 quarters · filed 2026-08-06 | $258.76M 10-Q · filed 2025-11-06 | $346.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $68.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $166.62M 10-Q · filed 2026-08-06 | $254.77M derived: sum of 3 quarters · filed 2026-08-06 | $411.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $97.92M 10-Q · filed 2026-05-07 | $186.08M derived: sum of 2 quarters · filed 2026-05-07 | $342.59M derived: sum of 3 quarters · filed 2026-05-07 | $416.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $88.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $244.67M derived: sum of 2 quarters · filed 2026-02-24 | $319.01M derived: sum of 3 quarters · filed 2026-02-24 | $460.77M 10-K · filed 2026-02-24 |
| 2024-09-30 | $156.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $230.85M derived: sum of 2 quarters · filed 2025-11-06 | $372.61M 10-Q · filed 2025-11-06 | $480.18M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $74.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $216.10M 10-Q · filed 2025-08-07 | $323.67M derived: sum of 3 quarters · filed 2026-02-24 | $416.68M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $141.76M 10-Q · filed 2025-05-08 | $249.33M derived: sum of 2 quarters · filed 2026-02-24 | $342.34M derived: sum of 3 quarters · filed 2026-02-24 | $342.34M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $107.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $200.58M derived: sum of 2 quarters · filed 2026-02-24 | $200.58M derived: sum of 3 quarters · filed 2026-02-24 | $205.90M 10-K · filed 2026-02-24 |
| 2023-09-30 | $93.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $93.01M derived: sum of 2 quarters · filed 2024-11-07 | $98.33M 10-Q · filed 2024-11-07 | $193.96M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.32M 10-Q · filed 2024-08-08 | $100.95M derived: sum of 3 quarters · filed 2025-02-27 | $165.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $5.32M 10-Q · filed 2024-05-09 | $100.95M derived: sum of 2 quarters · filed 2025-02-27 | $165.30M derived: sum of 3 quarters · filed 2025-02-27 | $205.59M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $95.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $159.97M derived: sum of 2 quarters · filed 2025-02-27 | $200.26M derived: sum of 3 quarters · filed 2025-02-27 | $245.82M 10-K · filed 2025-02-27 |
| 2022-09-30 | $64.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $104.64M derived: sum of 2 quarters · filed 2023-11-07 | $150.19M 10-Q · filed 2023-11-07 | $291.74M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $40.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $85.84M 10-Q · filed 2023-08-08 | $227.40M derived: sum of 3 quarters · filed 2024-02-28 | $429.26M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $45.55M 10-Q · filed 2023-05-10 | $187.11M derived: sum of 2 quarters · filed 2024-02-28 | $388.98M derived: sum of 3 quarters · filed 2024-02-28 | $700.39M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $141.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $343.42M derived: sum of 2 quarters · filed 2024-02-28 | $654.84M derived: sum of 3 quarters · filed 2024-02-28 | $725.21M 10-K · filed 2024-02-28 |
| 2021-09-30 | $201.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $513.28M derived: sum of 2 quarters · filed 2022-11-03 | $583.65M 10-Q · filed 2022-11-03 | $819.67M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $311.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $381.78M 10-Q · filed 2022-08-04 | $617.80M derived: sum of 3 quarters · filed 2023-02-28 | $794.73M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $70.37M 10-Q · filed 2022-05-05 | $306.39M derived: sum of 2 quarters · filed 2023-02-28 | $483.32M derived: sum of 3 quarters · filed 2023-02-28 | $1.01B derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $236.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $412.95M derived: sum of 2 quarters · filed 2023-02-28 | $934.74M derived: sum of 3 quarters · filed 2023-02-28 | $947.66M 10-K · filed 2023-02-28 |
| 2020-09-30 | $176.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $698.72M derived: sum of 2 quarters · filed 2021-11-04 | $711.64M 10-Q · filed 2021-11-04 | $775.42M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $521.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $534.72M 10-Q · filed 2021-08-05 | $598.50M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $12.92M 10-Q · filed 2021-05-06 | $76.70M derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $63.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $417.66M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $353.88M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $426.08M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |